cyclopropenone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, K; Fan, Y; Li, H; Li, Z; Si, H; Sun, H; Sun, P; Tang, G; Yao, SQ; Yin, Z; Zhang, Z; Zhang, ZM; Zhong, L; Zhu, C | 1 |
| Ding, K; Fan, Y; Li, Z; Lv, S; Xu, F | 1 |
2 other study(ies) available for cyclopropenone and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery".
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopropanes; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Glutathione S-Transferase pi; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2021 |
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Binding Sites; Cell Line, Tumor; Fatty Acid-Binding Proteins; Humans; Triple Negative Breast Neoplasms | 2023 |